- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02393950
Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers (FIMPAM)
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of ODM-106: A Randomised, Double-blind, Placebo-controlled Single Centre Study in Healthy Males
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eight planned dose levels of ODM-106 will be compared with placebo.There will be 2 panels of subjects with 4 dose levels in each panel. Subjects will be randomised to receive 3 dose levels of active treatment (single doses) and 1 dose of placebo. The dose levels will be escalated from the smallest dose upwards within the study and within the study subject. A third panel of 8 subjects may be included to investigate further dose levels of ODM-106, investigate the effect of taking ODM-106 with food or to compare two different formulations of ODM-106. For an individual subject, the study will consist of a screening period (maximum 4 weeks), 4 study treatment periods with a wash-out period between each study treatment administration and a post-treatment period of about 2 weeks.
The study duration for an individual will be approximately 12-16 weeks. Blood samples will be collected for the assessment of the concentration of ODM-106 and its metabolite.Plasma samples and cumulative urinary samples will be collected for metabolite screening. Safety will be assessed by a 12-lead electrocardiogram (ECG), continuous ECG monitoring, Holter ECG, supine and orthostatic blood pressure and heart rate, body temperature, physical examination, electroencephalogram (EEG), laboratory safety assessments and adverse events. Sedation and psychomotor tests and a quantitative EEG will also be performed.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Parexel International GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained.
- Participants must be able to speak, read and understand German.
- Good general health ascertained by detailed medical history and physical examinations.
- Males 18-45 years (inclusive).
- Body mass index (BMI) 18-30 kg/m2 inclusive
- Weight 55-95 kg (inclusive).
- Participants with female partners of child-bearing potential must adhere to a proper form of contraception from first study treatment administration until 3 months after the end-of-study visit.
Exclusion Criteria:
- A predictable poor compliance or inability to understand and comply with protocol requirements, instructions and protocol-stated restrictions or communicate well with the investigator.
- Vulnerable subjects.
- Veins unsuitable for repeated venipuncture.
- Evidence of clinically relevant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator. The participants should be healthy subjects.
- Subjects with a medical history of relevant psychiatric disorders or evidence of significant neuropsychiatric disease
- Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant medication during the study.
- Definite or suspected personal history of hypersensitivity to drugs or excipients.
- Intake of any medication that could affect the outcome of the study, as judged by the investigator, within 2 weeks before first study treatment administration (2 months for enzyme inducing drugs like rifampicin or carbamazepin), or less than 5 times the half-life of the medication.
- A history of alcoholism or excess alcohol intake (including regular consumption of more than 21 units of alcohol per week) .
- Use of nicotine-containing products within 6 months of admission and inability to refrain from using nicotine-containing products during the study.
- History of drug abuse or positive drug screen for amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methamphetamine or methadone.
- Propensity to get headache when refraining from caffeine-containing beverages.
- Blood donation or loss of clinically relevant amount of blood within 2 months before the screening visit.
- Abnormal 12-lead ECG finding of clinical relevance at the screening visit
- Heart rate (HR) < 50 bpm or > 90 bpm after 10 min in rest (supine) at the screening visit
- At the screening visit: systolic BP < 90 mmHg or > 140 mmHg, diastolic BP < 50 mmHg or > 90 mmHg, orthostatic hypotension decrease of greater than or equal to 20 mmHg for systolic BP, decrease of greater than or equal to 10 mmHg for diastolic BP.
- Abnormal 24-h Holter of clinical relevance at the screening visit,
- Positive serology to human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies.
- Any abnormal value of laboratory, vital signs, or physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part in the study.
- Participation in an investigational drug study within 2 months before entry into this study.
- An employee, a direct or indirect relative of the employee of the contract research organisation or the sponsor.
- Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the subject.
- Subject with abnormal standard EEG judged as clinically relevant by the investigator at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug: ODM-106
Oral capsules dosage 2-800mg once daily for one day
|
Single oral escalating doses of ODM-106 will be administered.
Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
|
Placebo Comparator: Drug: Placebo
Oral capsules given once daily for one day
|
Single oral escalating doses of ODM-106 will be administered.
Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.
Time Frame: From screening up to 16 weeks
|
Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.
|
From screening up to 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Plasma Concentration (cMax) of ODM-106
Time Frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
|
cMax of ODM-106 after single dosing of either Capsule B or Capsule A
|
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106
Time Frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level
|
AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.
|
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level
|
Time to Peak Plasma Concentration (Tmax) of ODM-106
Time Frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level
|
tmax of ODM-106 after single oral dosing of Capsule B or Capsule A
|
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level
|
Elimination Half-life of ODM-106
Time Frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
|
Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A
|
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
|
Metabolite Screening in Plasma and Urine
Time Frame: Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level
|
Metabolite screening in plasma and urine after single dosing
|
Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level
|
Effect of ODM-106 on Growth Hormone Levels
Time Frame: Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.
|
Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.
|
Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.
|
Sedation Scores on a Visual Analogue Scale (VAS)
Time Frame: Pre-dose and at 1, 6 and 10.5h post dose at each dose level
|
Assessment of sedation by subject
|
Pre-dose and at 1, 6 and 10.5h post dose at each dose level
|
Dexterity and Reaction Times
Time Frame: Pre-dose and at 1 and 6h post dose at each dose level
|
Selected battery of psychomotor tests
|
Pre-dose and at 1 and 6h post dose at each dose level
|
Quantitative EEG
Time Frame: Pre-dose and at 1, 6 and 10 h post dose at each dose level
|
Quantitative analysis of EEG
|
Pre-dose and at 1, 6 and 10 h post dose at each dose level
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rainard Fuhr, MD, Parexel International GmbH, Berlin, Germany
- Study Director: John Whiteside, Orion Corporation, Orion Pharma
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 3117001
- 2014-001317-33 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer Study
-
Atea Pharmaceuticals, Inc.RecruitingHealthy Volunteer StudyUnited States
-
BenevolentAI BioRecruitingHealthy Volunteer StudyUnited Kingdom
-
Atea Pharmaceuticals, Inc.Completed
-
Atea Pharmaceuticals, Inc.Completed
-
Atea Pharmaceuticals, Inc.Hoffmann-La RocheCompletedHealthy Volunteer StudyCanada
-
Reckitt Benckiser Healthcare (UK) LimitedSimbec ResearchCompletedHealthy Volunteer Study
-
Orion Corporation, Orion PharmaCompleted
-
Atea Pharmaceuticals, Inc.Not yet recruiting
-
Comanche BiopharmaRecruiting
Clinical Trials on ODM-106
-
Orion Corporation, Orion PharmaEndo PharmaceuticalsCompleted
-
Orion Corporation, Orion PharmaCompletedProstate CancerUnited States, United Kingdom, Finland, France, Estonia, Czech Republic
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaQuotient ClinicalCompleted
-
Orion Corporation, Orion PharmaCompletedSolid TumoursFrance, Finland, Spain, Italy, Denmark, United Kingdom
-
Orion Corporation, Orion PharmaEndo PharmaceuticalsCompletedProstate CancerUnited States, United Kingdom, Finland, France, Czech Republic, Estonia
-
Orion Corporation, Orion PharmaCompleted
-
BayerRecruitingCancerKorea, Republic of, Spain, United States, China, Australia, Austria, Belgium, Brazil, Colombia, Czechia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Netherlands, Peru, Poland, Portugal, Romania, Russian... and more
-
Orion Corporation, Orion PharmaBayerCompleted
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownMetastatic Castrate-resistant Prostate (CRPC) CancerFrance